Otonomy, Inc.

OTCPK:OTIC Stock Report

Market Cap: US$582.5k

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Otonomy Past Earnings Performance

Past criteria checks 0/6

Key information

11.07%

Earnings growth rate

28.37%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate-47.97%
Return on equity-244.24%
Net Marginn/a
Last Earnings Update30 Sep 2022

Recent past performance updates

Recent updates

Seeking Alpha Aug 01

Otonomy crashes 73% as mid-stage trial for tinnitus candidate fails

The shares of neurology focused Otonomy (NASDAQ:OTIC) plunged ~73% in the pre-market Monday after the company said its Phase 2 trial for OTO-313 did not demonstrate a clinically meaningful benefit for OTO-313 compared to placebo in hearing disorder tinnitus. "These results were unexpected with a much higher placebo response than observed in the prior Phase 1/2 study,” Chief Executive David A. Weber noted, adding that the company would discontinue further development of OTO-313 and take other steps to extend cash runway. This is a developing story. Check back for more updates.
Seeking Alpha Jul 25

Otonomy GAAP EPS of -$0.19 beats by $0.01

Otonomy press release (NASDAQ:OTIC): Q2 GAAP EPS of -$0.19 beats by $0.01. Cash Position: Cash, cash equivalents, and short-term investments totaled $53.1 million as of June 30, 2022, compared to $77.4 million as of December 31, 2021. Outlook: Financial Guidance: Otonomy expects that GAAP operating expenses for 2022 will be in the range of $52-$54 million, and that non-GAAP operating expenses will be in the range of $42-$44 million.
Seeking Alpha Apr 04

Otonomy: Hearing Loss And Tinnitus Data In 2022

Data for OTO-413 in hearing loss is due early in Q2 2002. Data for OTO-313 in tinnitus is due mid-2022. Tinnitus and hearing loss are indications with no FDA-approved medicines and are each billion-dollar markets. Precedent suggests developing therapeutics for these indications is an extremely difficult task.
Analysis Article Jun 16

Shareholders Will Probably Hold Off On Increasing Otonomy, Inc.'s (NASDAQ:OTIC) CEO Compensation For The Time Being

Shareholders of Otonomy, Inc. ( NASDAQ:OTIC ) will have been dismayed by the negative share price return over the last...
Analysis Article Feb 02

Is Otonomy (NASDAQ:OTIC) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Dec 11

Are Institutions Heavily Invested In Otonomy, Inc.'s (NASDAQ:OTIC) Shares?

A look at the shareholders of Otonomy, Inc. ( NASDAQ:OTIC ) can tell us which group is most powerful. Institutions will...

Revenue & Expenses Breakdown

How Otonomy makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:OTIC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 220-521435
30 Jun 220-531437
31 Mar 220-531436
31 Dec 210-511535
30 Sep 210-481531
30 Jun 210-461529
31 Mar 210-451528
31 Dec 200-451528
30 Sep 200-451529
30 Jun 200-441330
31 Mar 201-441232
31 Dec 191-451233
30 Sep 191-471335
30 Jun 191-491636
31 Mar 191-511935
31 Dec 181-502032
30 Sep 181-562228
30 Jun 181-652831
31 Mar 181-743435
31 Dec 171-904343
30 Sep 171-984851
30 Jun 171-1044955
31 Mar 171-1115159
31 Dec 161-1115060
30 Sep 160-1054559
30 Jun 160-944053

Quality Earnings: OTIC is currently unprofitable.

Growing Profit Margin: OTIC is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OTIC is unprofitable, but has reduced losses over the past 5 years at a rate of 11.1% per year.

Accelerating Growth: Unable to compare OTIC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OTIC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.6%).


Return on Equity

High ROE: OTIC has a negative Return on Equity (-244.24%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/04/13 11:08
End of Day Share Price 2023/04/11 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Otonomy, Inc. is covered by 9 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aaron GalBernstein
Sumant Satchidanand KulkarniBofA Global Research
Charles DuncanCantor Fitzgerald & Co.